Overview

  • Product name

    Anti-Chk2 (phospho T383) antibody
    See all Chk2 primary antibodies
  • Description

    Rabbit polyclonal to Chk2 (phospho T383)
  • Host species

    Rabbit
  • Specificity

    Detects Human Chk2 only when phosphorylated at threonine 383 (Mouse: Thr387; Rat: Thr386)
  • Tested applications

    Suitable for: WB, ELISA, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic phosphopeptide derived from human Chk2 around the phosphorylation site of threonine 383 (M-R-TP-L-C).

  • Positive control

    • COS7 cells

Properties

Applications

Our Abpromise guarantee covers the use of ab59408 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 61 kDa (predicted molecular weight: 61 kDa).
ELISA 1/20000.
ICC/IF Use at an assay dependent concentration.

Target

  • Function

    Regulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
  • Tissue specificity

    High expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
  • Involvement in disease

    Defects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53.
    Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
    Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
  • Sequence similarities

    Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily.
    Contains 1 FHA domain.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications

    Phosphorylated by PLK4.
  • Cellular localization

    Nucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
  • Information by UniProt
  • Database links

  • Alternative names

    • CDS 1 antibody
    • Cds1 antibody
    • Cds1 homolog antibody
    • Checkpoint kinase 2 antibody
    • Checkpoint like protein CHK2 antibody
    • CHEK 2 antibody
    • Chek2 antibody
    • Chk 2 antibody
    • CHK2 checkpoint homolog (S. pombe) antibody
    • CHK2 checkpoint homolog antibody
    • CHK2_HUMAN antibody
    • hCds1 antibody
    • HuCds 1 antibody
    • LFS 2 antibody
    • LFS2 antibody
    • PP1425 antibody
    • RAD 53 antibody
    • RAD53 antibody
    • Rad53 homolog antibody
    • Serine/threonine protein kinase Chk2 antibody
    • Serine/threonine-protein kinase Chk2 antibody
    see all

Images

  • All lanes : Anti-Chk2 (phospho T383) antibody (ab59408) at 1/500 dilution

    Lane 1 : COS7 cell extracts, UV treated (30 mins)
    Lane 2 : COS7 cell extracts, UV treated (30 mins) with immunising phosphopeptide

    Predicted band size: 61 kDa
    Observed band size: 61 kDa

  • HeLa (human epithelial cell line from cervix adenocarcinoma) cells stained for Chk2 (phospho T383) (green) using ab59408 at 1/100 dilution in ICC/IF, in the presence (right panel) or absence (left panel) of immunizing phosphopetide.

  • ab59408 staining Chk2 (phospho T383) in human colon carcinoma cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilized with 0.5% Triton X-100 and blocked with 1% BSA for 30 minutes at 37°C. Samples were incubated with primary antibody (1/100 in PBS + 1% BSA) for 1 hour at 37°C. A FITC-conjugated goat anti-rabbit IgG polyclonal (1/100) was used as the secondary antibody.

    See Abreview

References

This product has been referenced in:

  • Dias MH  et al. Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors. Mol Oncol 13:290-306 (2019). Read more (PubMed: 30422399) »
  • Liu X  et al. Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells. J Exp Clin Cancer Res 38:184 (2019). Read more (PubMed: 31053160) »
See all 9 Publications for this product

Customer reviews and Q&As

1-5 of 5 Abreviews or Q&A

Application
Immunocytochemistry/ Immunofluorescence
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: 37°C
Sample
Human Cell (Colon carcinoma cells)
Specification
Colon carcinoma cells
Permeabilization
Yes - 0.5% Triton
Fixative
Paraformaldehyde

Dr. Eleni Petsalaki

Verified customer

Submitted Mar 03 2014

Application
Western blot
Loading amount
50 µg
Gel Running Conditions
Non-reduced Denaturing (8%)
Sample
Human Cell lysate - whole cell (Human Colon carcinoma BE cells)
Specification
Human Colon carcinoma BE cells
Treatment
Etoposide 10 μM for 8 h
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Dr. Eleni Petsalaki

Verified customer

Submitted Jan 28 2013

Answer

Vielen Dank für das Senden des ausgefüllten Fragebogens.

Ich habe mir das Protokoll auch mit dem Labor angeschaut.

Das Labor hat keineBanden bei100 oder 150 kD erhalten. Es könnte jedoch sein, dass je nach Probenzubereitung, es noch Aggregate hat in den Proben. Ich habe Ihnen daher im Anhang eine Empfehlung zur Probenzubereitung getan, welche Aggregate und Dimere ausschliessen soll. Vielleicht könnte dies helfen, das Problem zu lösen.

Können Sie mir bitte auch (nochmals)bestätigen, dass der sekundäre Antikörper mit anderen primären Antikörpern gut funktioniert?

Falls dies das Problem nicht lösen wird, werden wir Ihnen den Antikörper gerne ersetzen.

Read More

Answer

Vielen Dank für Ihren Anruf.

Es tut mir leid zu hören, dass Sie Probleme mit diesem Antikörper haben.

Ich habeden besprochnenFragebogen als Word-Dokument an diese E-Mail angehängt. Durch das Ausfüllen des Fragebogens erhalten wir alle nötigen Informationen über Ihre Proben und Ihr Protokoll. Sobald Sie dieses Formular an uns zurückgeschickt haben, werden wir uns Ihr Protokoll ansehen und uns wieder bei Ihnen melden.Ich wäre Ihnen dankbar, wenn Sie auch einen Scan des Resultates mitschicken könnten.Ich kann dann das Labor anfragen, ob auch andereZellen getestet wurdenundauch Banden bei 100 oder 150kD gesehen wurden.
Falls der Antikörper nicht so funktioniert, wie auf dem Datenblatt beschrieben und er innerhalb der letzten 180 Tage gekauft wurde, werden wir Ihnen gerne einen Ersatzantikörper Ihrer Wahl oder eine Gutschrift/Rückerstattungschicken.

Ich freue mich, bald wieder von Ihnen zu hören.

Read More
Application
Western blot
Sample
Xenopus laevis Cell lysate - other (One egg or embryo equivalent loaded per lane)
Loading amount
1 cells
Specification
One egg or embryo equivalent loaded per lane
Treatment
100 µM Bleomycin for 18 hours
Gel Running Conditions
Reduced Denaturing (10% polyacrylamide)
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

Dr. Thomas Mcgarry

Verified customer

Submitted Jan 16 2012

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up